Strategies to Enhance Drug Loading and Functionality in Polymeric Ultrasound Contrast Agents by Soe, Mi Thant Mon
  
 
 
 
 
Strategies to Enhance Drug Loading and Functionality in 
Polymeric Ultrasound Contrast Agents 
 
 
A Thesis  
Submitted to the Faculty  
of 
 Drexel University 
by 
Mi Thant Mon Soe 
in partial fulfillment of the 
requirements for the degree  
of 
Master of Science in Biomedical Engineering 
September 2014 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
© Copyright 2014 
Mi Thant Mon Soe. All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
  
Acknowledgements 
Firstly, I would like to acknowledge Dr. Wheatley for her guidance, patience and 
input throughout the process.  She has given me an unforgettable research experience and 
a basement full of awesome lab mates. I have known her from my first freshmen class, 
when she waltzed into the freshmen engineering lab with unbound enthusiasm. For the 
past five years, she has continually cheered me up with her gigantic, bubbly personality; 
making her an integral part of my Drexel experience. 
I would also like to thank my committee members: Dr. John Eisenbrey and Dr. 
Sriram Balasubramanian for their time, wisdom and interest in my research. In addition, I 
need to thank in particular Tarn Teraphongphom, Lauren Jablonowski, Reva Street and 
Dr. Michael Cochran for teaching and inspiring my work in the basement. I would also 
like to thank the previous students from the Wheatley lab who have worked on the 
standard fabrication, and testing protocols that I had an opportunity to utilize for my 
project. Furthermore, I would like to thank the other undergraduate students from my lab 
- Nick Daroshefski, David Brown and Lorenzo Albala, and friends from other labs who 
have made my thesis work possible through their assistance. 
Finally, I would like to thank my most caring, wonderful and amazing parents, the 
rest of the family, all of my friends and the e-board of the International Students Union 
for their love and support. I am grateful that they have never given up on me; especially, 
my best friends, Giang Nguyen and Ian Kennedy.  Collectively, I would like to thank 
every single person who has touched and shaped the current Thant, who was able to 
complete this master thesis.  
 
  
Table of contents 
LIST OF TABLES 4 
LIST OF ABBREVIATIONS 5 
ABSTRACT 6 
1. INTRODUCTION 8 
1.1.  Overall Design Objective 10 
2. BACKGROUND 11 
2.1. Cancer and Cancer Therapies 11 
2.2. Ultrasound 13 
2.3. Ultrasound Contrast Agents 14 
2.5. Nanoparticles 17 
2.5.1. Magnetic Nanoparticles 18 
3. DESIGN ASPECTS 21 
3.1.  Design Constraints and Criteria 22 
4. SPECIFIC AIMS 23 
5. MATERIALS AND METHODS 25 
5.1.   Materials 25 
5.1.1. Magnetic Nanoparticles 25 
5.1.2. Ultrasound Contrast Agent Polymers and Drug 25 
 
  
5.2. Methods 26 
5.2.1. Magnetic Nanoparticles Fabrication 26 
5.2.1.1. Fabrication of Oleic Acid Capped Magnetic Nanoparticles 26 
5.2.1.2. Fabrication of Pluronic Coated Oleic Acid Capped MNP 26 
5.2.2. Hydrophobic Doxorubicin Formulation 27 
5.2.3. Loading of Doxorubicin onto Magnetic Nanoparticles  28 
5.2.4. Magnetic Behavior of MNP Loaded with h-Dox:VSM 28 
5.2.5. Fabrication of Drug or Nanoparticle Loaded Ultrasound Contrast Agents 29 
5.2.6. Characterization of the Ultrasound Contrast Agents 30 
5.2.6.1. Zeta potential and Size of the Ultrasound Contrast Agent 30 
5.2.6.2. Cumulative Dose Response: Acoustic Enhancement Test 30 
5.2.6.3. Time Response: Stability Test 32 
5.2.6.4. Scanning Electron Microscopy 32 
5.2.7. Doxorubicin Loading 32 
5.3. Statistical Methods 33 
6. RESULTS AND DISCUSSION 34 
6.1. Aim 1 – Loading of Magnetic Nanoparticles on Ultrasound Contrast Agents 35 
6.1.1. Acoustic Properties of MNP-OA Loaded UCA 35 
6.1.2. Size and Surface Properties of the MNP-OA Loaded UCA 38 
6.1.3. Storage behavior of MNP-OA 41 
6.2. Aim 2 – Entrapment of Doxorubicin onto Magnetic Nanoparticles 42 
6.2.1. Characterization of MNP-OA-PA loaded UCA 44 
6.3. Aim 3 – Increasing Doxorubicin Loading onto Ultrasound Contrast Agents 48 
6.3.1. Doxorubicin Encapsulation 49 
6.3.2. Acoustic Properties of Hydrophobic Dox Loaded UCA 51 
6.3.3. Size and Surface Properties of the Hydrophobic Dox Loaded UCA 53 
 
  
7. CONCLUSIONS AND CONTRIBUTIONS TO SCIENCE 57 
8. FUTURE RECOMMENDATIONS 59 
9. REFERENCES 61 
10.   APPENDIX 67 
 
1 
 
List of Figures 
Figure 1-1 Proposed structure of the poly (lactic acid) ultrasound contrast agent loaded 
with magnetic nanoparticles ....................................................................................... 9 
Figure 2-1 The chemical structure of Doxorubicin [16]. .................................................. 12 
Figure 2-2 Chemical structure of poly (lactic acid) [33] .................................................. 15 
Figure 2-3 Poly (lactic acid) ultrasound contrast agent loaded with hydrophilic 
doxorubicin ............................................................................................................... 17 
Figure 2-4 Structure of the oleic acid [46] ........................................................................ 19 
Figure 2-5 Hydrophobic magnetic nanoparticles capped with oleic acid ......................... 19 
Figure 2-6 Structure of the Pluronic F127 [47] ................................................................ 20 
Figure 2-7 Hydrophilic magnetic nanoparticles capped with oleic acid and coated with 
pluronic acid.............................................................................................................. 20 
Figure 5-1 Schematic of the in vitro acoustic testing set-up, image courtesy of Tarn 
Teraphongphom ........................................................................................................ 31 
Figure 6-1 The effect of varying MNP capped with oleic acid loading on the acoustic 
enhancement of UCA. (n=3, error bars =SEAM) ..................................................... 36 
Figure 6-2 The effect of varying MNP capped with oleic acid loading on the stability of 
the UCA. (n=3, error bars = SEAM) ........................................................................ 37 
Figure 6-3 The effect of varying the loading mass of MNP capped with oleic acid on the 
size of UCA. (n=3 except 50 wt% MNP-OA, n=2, error bars = SEAM) ................. 38 
Figure 6-4 The effect of varying the loading mass of MNP capped with oleic acid on the 
polydispersity of the UCA made. (n=3, error bars = SEAM) ................................... 39 
2 
 
Figure 6-5 SEM images comparing the morphology of the UCA loaded with MNP 
capped with oleic acid. Top row has magnification of 10 000x while the bottom row 
is at 3000x. All size bars are 1um. Image (A) unloaded control UCA (B) 33wt% 
MNP-OA (C) 50wt% MNP-OA (D) unloaded control UCA (E) 33wt% MNP-OA 
(F) 50wt% MNP-OA................................................................................................. 40 
Figure 6-6 The effect of varying the loading mass of the MNP capped with oleic acid on 
the zeta potential of the UCA. (n=3, error bars = SEAM) ........................................ 41 
Figure 6-7 Comparison in magnetization with and without loading h-Dox on MNP 
capped with oleic acid and coated with pluronic acid. It was measured at 300K. at 
room temperature. ..................................................................................................... 43 
Figure 6-8 The effect of varying the loading mass of MNP capped with various molecules 
on the size of UCA. (n=1, error bars = SEAM) ........................................................ 45 
Figure 6-9 The effect of varying the loading mass of MNP capped with various molecules 
on the polydispersity index of UCA. (n=1, error bars = SEAM) .............................. 45 
Figure 6-10 SEM images comparing the morphology of the UCA loaded with MNP-OA-
PA. Magnification is 3500x. All size bars are 2.5μm. Image (A) 250mg MNP-OA-
PA in Aq (B) 56mg MNP-OA-PA in Aq (C) 26mg MNP-OA-PA in Aq (D) blank 
control UCA (E) 54mg pluronic acid in Aq.............................................................. 46 
Figure 6-11 The effect of varying the loading mass of MNP capped with various 
molecules on the zeta potential of UCA. (n=1, error bars = SEAM)........................ 47 
Figure 6-12 Proposed design of the final design where h-Dox was encapsulated into the 
PLA shell .................................................................................................................. 48 
3 
 
Figure 6-13 The effect of varying the loading of different forms of Dox on the drug 
payload. (n=3, error bars = SEAM) (p<0.0001) ....................................................... 50 
Figure 6-14 The effect of varying the loading of different forms of Dox on the 
encapsulation efficiency. (n=3, error bars = SEAM) ................................................ 51 
Figure 6-15 The effect of varying the loading of different forms of Dox on the acoustic 
enhancement of UCA. (n=3, error bars = SEAM. .................................................... 52 
Figure 6-16 The effect of varying the loading of different forms of Dox on the stability of 
UCA. (n=3, error bars = SEAM) .............................................................................. 53 
Figure 6-17 The effect of varying the loading of different forms of Dox on the size of 
UCA. (n=3 for all except 5.66wt% h-Dox which has n=1, error bars = SEAM) ..... 54 
Figure 6-18 The effect of varying the loading of different forms of Dox on the 
polydispersity index of the UCA. (n=3 for all except 5.66wt% h-Dox which has n=1, 
error bars = SEAM) .................................................................................................. 54 
Figure 6-19 SEM images comparing the morphology of the UCA loaded with 
doxorubicin. Magnification is 3500x. All size bars are 2.5μm. Image (A) blank 
control UCA (B) 3wt% hydrophilic Dox (C) 5.66wt% h-Dox (D) 3wt% hydrophilic 
Dox ............................................................................................................................ 55 
Figure 6-20 The effect of varying the loading of different forms Dox on the zeta potential 
of UCA. (n=3, error bars = SEAM) .......................................................................... 56 
Figure 10-1 Standard curve of h-Dox in water used to calculate the encapsulation 
efficiency on MNP capped with oleic acid and coated with pluronic acid (n=3, error 
bars = SEAM) ........................................................................................................... 67 
4 
 
Figure 10-2 Standard curve of hydrophilic Dox in DMSO used to calculate the 
encapsulation efficiency on UCA (n=3, error bars=SEAM, Ex= 495nm, Em= 
585nm, Gain=118 dB) .............................................................................................. 67 
Figure 10-3 Standard curve of h-Dox in DMSO used to calculate the encapsulation 
efficiency on UCA (n=3, error bars=SEAM, Ex= 485nm, Em= 591nm, Gain=120 
dB)............................................................................................................................. 68 
 
List of Tables  
Table 1 Commercially available ultrasound contrast agents ………...………………….15 
 
 
 
 
 
 
 
 
 
 
5 
 
List of Abbreviations 
 
Aq: Aqueous 
DI water: Deionized water 
DMSO: Dimethyl sulfoxide 
Dox: Doxorubicin 
EPR: Enhanced permeation and retention  
h-Dox: hydrophobic Doxorubicin 
IPA: Isopropyl alcohol 
MNP: Magnetic nanoparticles 
MNP-OA: Magnetic nanoparticles capped with oleic acid 
MNP-OA-PA: Magnetic nanoparticles capped with oleic acid coated in Pluronic acid 
MRI: Magnetic resonance imaging 
MeCl: Methylene chloride 
MW: Molecular weight 
PBS: Phosphate buffered saline 
PDI: Poly dispersity index 
PLA: Poly (lactic acid) 
PVA: Poly (vinyl alcohol) 
SEM: Scanning electron microscopy 
TEA: Triethylamine 
UCA: Ultrasound contrast agents 
VSM: Vibrating sample magnetometer 
 
 
 
 
 
6 
 
 
Abstract 
Strategies to Enhance Drug Loading and Functionality in 
Polymeric Ultrasound Contrast Agents 
Mi Thant Mon Soe 
Margaret A. Wheatley, Ph.D. 
 
Ultrasound contrast agents (UCA) are currently studied to further improve their 
diagnostic capabilities and for better targeted delivery of genes and drugs, with a strong 
focus on cancer therapy. These injectable microbubbles that strongly interact with 
ultrasound can be loaded with chemotherapeutic drugs, such as hydrophilic Doxorubicin-
HCl (Dox-HCl), for successful targeted delivery upon rupturing under focused 
ultrasound. This reduces the harmful side effects of chemotherapeutic drugs that are 
administered systemically. Previous studies with UCA made from poly (lactic acid) 
(PLA) have shown maximum drug loading of 6.2 mg Dox-HCl/ g PLA at an initial 
loading concentration of 30 mg Dox-HCl/ g PLA. In order to increase the treatment 
efficiency, Dox loaded magnetic iron oxide nanoparticles (MNP) were encapsulated 
within the PLA shell. The inclusion of the MNP not only allows for increased Dox 
loading, but also provides more imaging capabilities, since MNP can be imaged using 
magnetic resonance imaging (MRI) even after ultrasound-induced rupture of UCA.  
Preliminary in vitro tests were performed to determine methods of maintaining 
the highest amount of ultrasound interaction, measured by acoustic enhancement, 
possible for magnetic nanoparticles capped with oleic acid (MNP-OA) loaded UCA. This 
was seen at 33wt% MNP-OA loading where the enhancement reached 14.77±0.61 dB. 
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The magnetic nanoparticles had a short shelf life and so, the MNP-OA were further 
coated with Pluronic acid to form MNP-OA-PA. The hydrophobic Dox (h-Dox), formed 
after removing the HCl, was loaded onto the MNP, between the oleic acid chains. 
However, there was a low entrapment of 2.88 μg Dox/ mg MNP. When these MNP-OA-
PA were loaded onto the UCA, the resulting UCA were non-echogenic. The problem was 
identified by loading just the Pluronic acid onto the UCA, which showed that UCA lose 
their echogenicity when formed in the presence of Pluronic acid. Low loading of Dox 
onto the MNP-OA together with the decreased acoustic enhancements made the design of 
Dox-loaded MNP-OA-PA encapsulated in UCA less than was hoped for.  
After the Dox-HCl was modified to make it more hydrophobic, they were loaded 
onto PLA UCA to determine whether the drug payload would increase since PLA is also 
hydrophobic. It was found that in the hydrophobic form, a maximum drug load of 
27.18±0.39 mg Dox / g PLA can be achieved upon initial loading of 30 mg Dox / g PLA 
for the 3wt% h-Dox loading, resulting in a significant increase (p<0.0001) in drug 
payload when compared to Dox-HCl loading. The highest acoustic enhancement of 
12.69±0.81dB was seen at the largest dose recorded (15.3 μg/mL) for the in vitro acoustic 
enhancement experiment. This increase in drug encapsulation would allow a higher dose 
of doxorubicin to be delivered to the patient while maintaining the desired acoustic 
characteristics. 
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1. INTRODUCTION 
Cancer is a leading cause of death worldwide and according to the International 
Agency for Research on Cancer, in 2012 alone, there were 8.2 million deaths [1]. This 
includes deaths from liver cancer (745 000 deaths) and breast cancer (521 000 deaths) 
[1]. Early detection of breast cancer, followed by chemotherapy can reduce recurrence 
and increase survival rates by at least 45% [2]. Liver cancer is the sixth leading cause of 
death in the world and its occurrence is higher in Southeast Asia and Africa where there 
is a higher number of patients with hepatitis B and C, both of which can lead to liver 
cancer. [3]. These two diseases that are closely associated with liver cancer are mainly 
treated by resection. In such underdeveloped areas of the world, only a small portion of 
the population can afford to get a surgical intervention. Chemotherapy is another form of 
treatment that is available and is cheaper.  
One of the main problems with chemotherapy is that it requires a cocktail of 
medications that work synergistically to kill the tumor cells over a period of time [4]. 
Unfortunately, these drugs can also kill the healthy cells, causing multiple side effects 
that make the patient weaker. In order to reduce these side effects, several targeted drug 
delivery designs have been formulated [5-7]. One of these designs previously developed 
in the Wheatley lab utilizes polymeric UCA which can be shattered using ultrasound [8]. 
These contrast agents were loaded with chemotherapeutic drugs such as doxorubicin 
(Dox) into their PLA shells and injected intravenously into the patient. Focused 
ultrasound waves can be used to shatter these drug loaded UCA near the tumor site, 
allowing more drug to reach the tumor cells, while avoiding healthy cells.  
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This project aims to increase the drug payload of the chemotherapeutic agent – 
Dox on the PLA UCA so that it may be possible to deliver a higher dose of the Dox to the 
tumor while administering the same amount of UCA, reducing systemic effects. In order 
to do this, Dox would be loaded onto magnetic nanoparticles (MNP) to increase the 
surface area onto which it can attach to. These Dox-MNP can then be encapsulated onto 
the PLA shell, increasing the overall Dox loading onto the UCA without compromising 
the acoustic properties (Figure 1-1). 
 
 
 
 
 
 
 
Figure 1-1 Proposed structure of the poly (lactic acid) ultrasound contrast agent loaded with magnetic 
nanoparticles 
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Overall Design Objective 
To increase the loading of the chemotherapeutic Doxorubicin onto the poly (lactic 
acid) shell UCA without compromising the acoustic properties of the UCA. This would 
decrease the systemic side effects of Dox and increase safety due to less ultrasound 
contrast agents being needed to achieve the same therapeutic effect. 
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2. BACKGROUND 
2.1. Cancer and Cancer Therapies 
Cancer is a general term used to refer to any condition caused by uncontrolled cell 
division. In 2013, it was expected that over 1 660 290 people in US would be diagnosed 
with cancer while 580 350 will die because of it. Between 2002 and 2008, the five years 
survival rate was 68% [9].  Current treatments include surgery, chemotherapy, radiation 
therapy, targeted therapy, immunotherapy, hyperthermia, stem cell transplant, and 
photodynamic therapy [10].  
Treatments such as chemotherapy are used to minimize the spread of the growth 
and spreading of the cancer cells to other parts of the body. The drugs that are used have 
a systemic effect on the body and damage not just the cancer cells but also the normal 
ones. This results in side effects such as immunosuppression and neutropenia [11]. 
Another problem with chemotherapy is its low efficacy due to its inability to reach some 
tumor sites resulting from irregular vasculature and multidirectional blood flow around 
the mass and the high inter tumoral pressure [12]. Thus, targeted drug delivery was 
developed to ensure that the chemotherapeutic drug works only at the tumor site.  
In this research, a commonly used chemotherapeutic drug, Doxorubicin (Dox) 
was used. Dox is an anthracycline antibiotic and has a molecular weight of 543.52 [13].  
The chemical structure of Doxorubicin [16]is shown in Figure 2-1. Doxorubicin 
hydrochloride (Dox-HCl) is a hydrophilic form of the drug and has a molecular weight of 
579.98. Dox disrupts the tumor cell proliferation by two different mechanisms. It can 
inhibit DNA replication by intercalating between the DNA base pairs. It also inhibits the 
topoisomerase II, preventing them from ligating back after the separation of the double 
12 
 
strands during DNA replication [14]. It has been used to treat many different cancers 
such as leukemia, breast, lung and thyroid carcinomas and bone sarcomas. Due to its 
mechanism of action, Dox also forms oxygen free radicals that lead to several reported 
cardiac problems such as atrial and centricular dysarrhythmias, pericardis-myocarditic 
syndrome, and chronic myopathy [15].  
 
 
Others have attempted to reformulate Dox in order to reduce side effects and 
protect the heart. Doxil
®
 is the FDA approved intravenous form of the drug formed by 
encapsulating the Dox-HCl in liposomes [17].  Due to its encapsulation within the 
liposome, Doxil
®
 has a significantly decreased cardiotoxicity when compared to the 
unencapsulated Dox [18]. However, it has been shown to cause Palmer Plantar 
Erythrodysthesia (PPE), a dermal condition, and complement activation-related pseudo-
allergy (CARPA), a reaction to the infusion of the Doxil
®
 into the body. To reduce the 
accumulation of Doxil
®
 to the skin which leads to PPE, the half-life of Doxil
®
 can be 
reduced. In addition, a more controlled release can be done to prevent these typical side 
effects from occurring [19].  
Figure 2-1 The chemical structure of Doxorubicin [16] 
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2.2. Ultrasound 
Ultrasound imaging is widely used in medical diagnosis for its noninvasiveness 
and low cost. Ultrasound imaging technique is based on sound waves which are reflected 
or scattered by heterogeneous tissues of the human body [20]. The receiver in the 
transducer would detect these scattered echoes, and with image processing techniques, 
real-time images could be produced of fetus, cardiovascular system or tumors. The 
unreflected waves would be converted to thermal energy when absorbed or continue to 
travel through the tissue until reflected by another boundary.  The heterogeneity of the 
tissues results in impedance mismatch, a phenomenon, caused by a difference in the 
density within parts of the tissue that result in a difference in the speed of the sound 
traveling through it. Acoustic impedance ( ) is defined as:  
                  Eq. 1 
where ρ is the density (kg/m3) of the medium and c is the speed of sound (m/s) through 
the medium [21].   
This difference must be at a macroscopic structural scale like that of the cells in 
the body and not at the molecular scale. This limitation is due to the type of transducers 
used in medical imaging; they are around 2 to 10 Hz, generating ultrasounds of 
wavelengths between 150 and 800 μm [22]. This makes it extremely difficult to image 
blood since the blood cells and other components are smaller than these wavelengths 
because they have to be small enough to pass through capillaries of 7 μm in diameter. In 
addition, there is the Doppler effect which is caused by the frequency shift in the echoes 
when they are reflected by the moving blood, resulting in generation of weak signals.  
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2.3. Ultrasound Contrast Agents 
Ultrasound contrast agents are used to enhance the ultrasound signal by 
effectively increasing the scattering of the sound waves from the blood, thereby 
increasing their probability to reach the transducer where signal reading takes place. To 
be small enough to pass through the small capillaries and still scatter enough ultrasound 
even when they are much smaller than the ultrasound wavelengths, UCA needs to be 
compressible. Thus, UCA are made with shells that stabilize the microbubbles, 
preventing the gas from dissolving into the surrounding liquid. The gas increases the 
impedance mismatch between the blood and the gas core mainly from the fact that the 
density of gas is much lower than that of water, which makes up 60% of the blood [23]. 
This affects the impedance which then affects the reflective coefficient (R) that 
determines the percentage of acoustic wave reflected. This relationship is defined as:  
    
     
     
    [21]    Eq. 2 
where    is the acoustic impedance of the first medium and    is the acoustic impedance 
of the second medium.  At 1 atm and 20˚C, the zair  is 415 Pa·s/m while zwater  is 1.48 10
6
 
Pa·s/m. Using the Eq. 2, the R would be approximately equal to 1, making UCA a good 
reflector of acoustic wave.  In addition, the greater the compressibility of the UCA when 
compared to the surrounding tissues, the greater its ability to reflect the ultrasound wave 
that has a wavelength greater than its own diameter.  Many different types of UCA have 
been designed; shells made from phospholipids, polymer or surfactants while the gas 
cores have ranged from air, to perfluorocarbons [24-26]. Table 1 lists the current 
commercially available UCA [27 -32]. 
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Agent  Diameter (µm)  Core Material  Shell Material  
Imagent 6 Perflexane Phospholipid 
Optison  4.7  Perfluoropropane  Albumin  
Sonovue * 2.5  Sulfur hexafluoride  Phospholipid  
Definity * 2.5 Octafluoropropane Phospholipid 
Sonazoid * 2.5 Perfluorobutane Hydrogenated egg 
phosphatidyl serine 
SonoRx † -  Air  Simethicone coated Cellulose  
* not FDA approved for use in the US but used outside the US 
† discontinued 
 
Previous studies conducted in the Wheatley lab have successfully fabricated 
polymer shells made of poly (lactic acid) that are filled with air which have in vitro 
acoustic enhancements of over 20 dB [8]. The mean diameter of the microbubbles is 2 
μm while the thickness of the shell is between 100 to 200 nm. Poly (lactic acid), shown in 
Figure 2-2, is an FDA approved molecule that can be broken down into the lactic acid 
which is a naturally occurring biodegradable metabolite, making it a suitable molecule to 
be used as a UCA shell.  
 
   Table 1. Commercially Available Ultrasound Contrast Agents [27-32] 
Figure 2-2 Chemical structure of poly (lactic acid) [33] 
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2.4. Ultrasound Assisted Chemotherapeutic Delivery 
One way to achieve controlled release is through the use of ultrasound contrast 
agents such as encapsulated air microbubbles which are small enough (1 to 6 μm) to pass 
through the lumens in the small capillaries of circulatory system [34]. During insonation 
at the tumor site, the microbubbles oscillate about a resonant diameter and then rupture 
into nanoparticles that can permeate through the leaky pores of the tumor vasculature.  
For targeted drug delivery, the drug can be loaded into the shell whereby the nano shards 
created during rupture would release the drug at the site of the tumor. Also, a sustained 
release is ensured as the drug would be gradually released as the polymer hydrolyses. 
This reduces systemic side effects of the drug agent.  In this research, the shell used was 
made from poly lactic acid (PLA). Three methods of loading the drug onto the PLA shell 
have been developed in the Wheatley lab [35]. The Dox can be either incorporated into 
the shell during the primary emulsion phase, or during the hexane washing step of the 
fabrication and lastly, Dox can be adsorbed onto the shell post fabrication due to 
electrostatic attraction between the drug and the polymer.  It was shown that the loading 
of the Dox during the hexane washing step had the maximum payload of 24.1 mg Dox/g 
PLA at the highest initial loading concentration of 40 mg Dox/g PLA. Thus, the 
maximum encapsulation efficiency reached was 60.2% (Figure 2-3) [8]. However, it was 
found that most of the drug was released as soon as the microbubbles were suspended in 
buffer. Encapsulation by incorporation is the preferred method due to its higher acoustic 
performance, but this does not give a high enough drug loading.  In order to increase the 
loading of the Dox onto the shell, nanoparticles that are loaded with the Dox can be 
incorporated. 
17 
 
 
 
2.5. Nanoparticles 
Nanoparticles can be made from a wide variety of organic and inorganic materials 
such as ceramics, polymers, lipids and metals [36].  To avoid toxicity via accumulation 
over time, they are required to be biodegradable or easily excreted through the kidneys. 
However, a recent study showed that nanoparticles that get coated by the patients’ serum 
protein via adsorption, preventing renal excretion, can be coated with zwitterionic or 
neutral organic coatings to prevent this adsorption [37]. This resulted in final 
hydrodynamic diameter of less than 5.5 nm in the body, resulting in rapid and efficient 
urinary excretion. Independent of the microcapsules, nanoparticles can themselves be 
used as drug delivering agents. This is feasible because they are smaller than the 
characteristic pore cutoff size in the tumor vasculature, which ranges from 200 nm to 1.2 
μm [38]. Nanoparticles can be detected by the reticulo-endothelial system (RES) which 
can opsonize and clear them away rapidly. In order to increase their half-life in the body, 
they can be coated with hydrophilic molecules to prevent rapid clearance [39]. There are 
many different materials that can be used as nanoparticles. Iron oxide nanoparticles 
would be used in this research.  
Figure 2-3 Poly (lactic acid) ultrasound contrast agent loaded with hydrophilic doxorubicin 
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2.5.1. Magnetic Nanoparticles 
Currently, iron oxide nanoparticles are used as contrast agents for X-ray phase 
computed tomography (SR-PCT) [40] and magnetic resonance imaging (MRI) [41].   
MNP improves an MRI scan by producing hypo-intense signaling of the transverse 
relaxation time (T2) and the apparent transverse relaxation time (T2
*
).  
Intravenous iron oxide particles are superparamagnetic, that is, they retain no 
magnetic moment in the absence of a field. Saturation magnetization of MNP represents 
the magnetization that results from the alignment of their magnetic dipoles to the external 
field. A greater saturation magnetization ensures the localized changes in the longitudinal 
and transverse relaxation times of the water molecules in the environment to improve the 
MRI contrast.  Since saturation magnetization is also correlated to the size, MNP need to 
be between 4 to 10 nm to be superparamagnetic [42]. They should also be above 5.5 nm 
to avoid rapid renal clearance [43].  One way to produce MNP is by a co-precipitation 
method. Different bases can be used in this method to change the average size of the 
MNP produced. This ranges from 3.8 nm to 11.5 nm [41]. The size of the MNP correlates 
to the surface area for the iron oxide-Dox conjugation to occur. In a recent study by Niu, 
multifunctional microbubbles were designed where Dox loaded PLGA microbubble 
shells were also loaded with free MNP [44]. The MNP enhanced both ultrasound and 
magnetic resonance imaging (MRI) of the lymph nodes while targeted chemotherapy is 
ensured. In other research, the Dox was conjugated to the iron oxide nanoparticles [45]. 
These work by releasing the Dox in response to the acidic pH of the environment of inner 
cellular organelles. MNP crystal cores can be capped with a capping agent such as oleic 
acid which has a molecular weight of 282.46 (Figure 2-4) (Figure 2-5) [46]. The 
19 
 
hydrophilic end of the molecule would be facing the MNP while the hydrophobic end 
would be unbound. The Dox molecule is expected to be attached to the hydrophobic 
chains of the oleic acid molecule.  
 
 
 
 
 
 
 
The oleic acid capped MNP can be further coated with Pluronic F127 to make it 
hydrophilic (Figure 2-6) (Figure 2-7) [47] [48]. The hydrophobic part of the Pluronic 
would interact with the hydrophobic part of the oleic acid while the hydrophilic ends of 
the Pluronic acid would be free floating.  
 
Figure 2-4 Structure of the oleic acid [46] 
Figure 2-5 Hydrophobic magnetic nanoparticles capped with oleic acid 
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Figure 2-6 Structure of the Pluronic F127 [47] 
Figure 2-7 Hydrophilic magnetic nanoparticles capped with oleic acid and coated with pluronic acid 
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3. DESIGN ASPECTS 
The criteria and constraints defined for this project ensured that the final targeted 
chemotherapeutic agent delivering UCA was modified without compromising the 
acoustic properties. These studies serve as a template for investigations that validate the 
increased drug loading of the UCA and their ability to be echogenic when used with 
ultrasound. 
The goal is to design PLA UCA that can deliver more of the model 
chemotherapeutic agent – Dox by first loading it onto MNP to increase the loading 
surface and then encapsulate these MNP onto the UCA. This must be done without 
sacrificing their acoustic properties or the size limitations. It would also give another 
potential mechanism for drug to enter the cell - via endocytosis of the MNP.  
Since the UCA resonate under the focused ultrasound, the UCA would only shatter near 
the tumor cells. The ultrasound can also increase the entry into the cell since the 
insonation would generate heat in the cell environment, causing the cell membrane to be 
more permeable to the nanoshards created when the UCA is ruptured.  
 
 
 
 
 
 
 
 
22 
 
3.1. Design Constraints and Criteria 
Constraints 
Microbubbles must have the following properties: 
 Microbubbles must be less than 5 μm in diameter to pass through the vascular 
bed. 
 Incorporation of nanocrystals must not compromise the acoustic properties of the 
microbubble in the area of acoustic enhancement. Enhancement of more than 12 
dB during in vitro tests has translated to successful in vivo imaging.  
 Ultrasound irradiation must be responsive within the range of the medical 
ultrasound.  
 The UCA must have at least 15 minute in vitro half-life in order to travel through 
the vasculature of the target tumor at least once when injected into the patient.  
 The MNP must be non-toxic and be easily eliminated from the body once it has 
interacted with the cancer cell. 
 
Criteria 
 Final UCA size must be 1-5 μm. 
 In vitro acoustic enhancement must be ≥ 12 dB. 
 Drug loading must be ≥ 6.5 mg Dox/g PLA, the highest achievable dose without 
nanocrystals. 
 In the presence of the ultrasound, the in vitro t1/2 must be ≥ 15 minutes. 
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4. SPECIFIC AIMS 
The main goal of this research is to increase the loading of the drug Dox in 
a PLA UCA developed in Wheatley lab, for greater treatment efficiency in cancer. 
This increased loading will be achieved by co-encapsulating nanocrystals (MNP) 
that are ligated to the drug as the means to increase the loading and supplement 
encapsulated Dox in the PLA shell. In addition, MNP could act as magnetic 
resonance imaging (MRI) contrast agents and X-ray phase computed tomography 
(SR-PCT) [40]. 
 
Aim 1: To develop and characterize PLA UCA which are loaded with MNP. 
 Assess the effect of loading MNP on the acoustic properties of UCA. This 
would ensure that the incorporation of the MNP do not affect the acoustic 
and drug delivery properties of the PLA microbubbles.  Dose and time 
acoustic response curves were constructed for UCA loaded with MNP. 
 Determine the largest loading MNP possible without significantly 
decreasing the echogenicity. 
 
Aim 2: To develop and characterize MNP conjugated with Dox. 
 Determine the highest drug payload possible on the MNP using different 
MNP capping agents. The method that achieves the highest yield of 
drug/particle will be chosen for specific aim 3.  
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Aim 3:  To increase the loading of the Dox into the shell of the UCA.  
 Determine the mass of Dox that was actually loaded on the UCA with and 
without the use of the different MNP. 
 Modify the UCA fabrication process or the drug formulation to further 
increase the drug loading.  
 Perform acoustic tests to determine echogenicity after loading. 
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5. MATERIALS AND METHODS 
5.1.      Materials 
5.1.1. Magnetic Nanoparticles 
Fe(III) chloride hexahydrate (lot# MKBH8430V) from Sigma-Aldrich (St. Louis, 
MO), Fe(II) chloride tetrahydrate (lot# BCBH6730V) from Sigma-Aldrich (St. Louis, 
MO), oleic acid (lot#MKBH5625V) from Aldrich (St. Louis, MO), 1N ammonium 
hydroxide (lot# 1353221) from Fluka (Pittsburgh, PA), and Pluronic® F-127 (lot# 
SLBG6026V) from Sigma (St. Louis, MO) were used.  
 
5.1.2. Ultrasound Contrast Agent Polymers and Drug 
Poly (lactic acid) (PLA) 100 DL 7E = 115 kDa (lot# LY00414-119) from Evonik 
Industries (Birmingham, AL), ammonium carbonate (lot#124326) from Fisher Scientific 
(Fair Lawn, NJ), poly (vinyl alcohol) (MW = 25 kDa, 88 mol% hydrolyzed) (lot# 
652279) from Polysciences (Warrington, PA), isopropyl alcohol (IPA) (lot#B0522292)  
from Acros (New Jersey, NJ), methylene chloride (lot#135806), and hexanes 
(lot#110593) from Fisher Scientific (Waltham, MA), camphor (lot# 082K2515), 
chloroform (lot# SHBB7668V), dimethyl sulfoxide (DMSO) (lot#SHBC2572V) and 
triethylamine (TEA) (lot# 128K1103) from Sigma-Aldrich (St. Louis, MO) and 
Doxorubicin HCl (lot# 20130702), (lot# A0325A) from Tecoland, (lot# 1000461729) 
from Fluka (Pittsburgh, PA) were used. 
All materials were used as received. 
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5.2. Methods 
5.2.1. Magnetic Nanoparticles Fabrication 
5.2.1.1. Fabrication of Oleic Acid Capped Magnetic Nanoparticles [48] 
A solution of 11.6 g of FeCl3.6H2O and 4.3 g of FeCl2.4H2O dissolved in 400 mL 
of deionized water was continuously purged with nitrogen gas and stirred at 90˚C. After 
dissolution, 15 mL of NH4OH was added, followed by a dropwise addition of 9 mL of 
oleic acid. The black magnetic gel was precipitated and decanted. The gel was washed 
twice with acetone by sonication in an ice bath using a 0.5-inch probe horn (CL4 tapped 
horn probe with 0.5″ tip, Misonix Inc., Farmingdale, NY) with a Misonix probe sonicator 
at 110 W for 30 seconds which is made up of 10 pulses of 3 seconds, separated by 1 
second each. The gel was reweighed to get yield mass and mixed with 10 mL of 
methylene chloride.   
5.2.1.2. Fabrication of Pluronic Coated Oleic Acid Capped Magnetic Nanoparticles [49] 
Solutions of 0.1 M FeCl3.6H2O (811 mg dissolved in 30 mL deionized water) and 
0.1 M FeCl2.4H2O (298 mg dissolved in 15 mL deionized water) were mixed under 
nitrogen gas for 5 min. 15 mL of 1 M ammonia solution was added dropwise over 1 min.  
It was stirred for an additional 20 min. An aliquot of 115.8 uL oleic acid was added and 
stirred at 80˚C for 30 min. It was then cooled to room temperature. Pluronic acid (100 
mg) was added and stirred overnight. The samples were washed with deionized water and 
then the MNP were collected with a magnet. The samples were ultracentrifuged using 4 
tubes of the 38 mL size in the Sorvall WX Ultra Series 80 ultracentrifuge (AH629, 
Thermo Electron Corporation) at 20000 rpm (72k g-force) for 30min at 10˚C. The MNP 
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were redispersed in 15 mL water and sonicated. The samples were ultracentrifuged at 
20000 rpm for 30 min at 10˚C. It was washed 3 times with deionized water. The MNP 
were redispersed in 15 mL water and sonicated in an ice bath using the Misonix probe 
sonicator at 110 W for 150 seconds which is made up of 10 pulses of 3 seconds on, 
separated by 1 second off each. It was ultracentrifuged at 1000 rpm (180 g-force) for 20 
min at 10˚ C to remove large aggregates. The samples were lyophilized in pre-weighed 
50 mL centrifuge tubes on a Virtis Benchtop freeze-dryer (Gardiner, NY) -76.5° C (in the 
vacuum drier chamber) and 17-20 μBar.  
5.2.2. Hydrophobic Doxorubicin Formulation [50] 
To a solution of 50 mg Dox-HCl dissolved in 100 mL water, 400 uL of 
Triethylamine was added. Approximately 800 mL of chloroform was used to extract the 
Dox-base from the water. Using a Buchi Rotavapor RE111 rotary evaporator at 60˚ C, the 
chloroform was separated from the h-Dox until approximately 10 mL was left. The h-
Dox was transferred into a preweighed glass vial and was evaporated to determine the 
mass of the h-Dox formed. The percentage yield was calculated using the following 
equation: 
100% 
WeightDoxInitial
WeightDoxFinal
Yield      Eq. 3 
There exists a small difference between molecular weight of Dox-HCl of 579.98 and h-
Dox of 543.52. However it was ignored for simplicity, and in line with the accuracy by 
which Dox and Dox.HCl could be measured. 
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5.2.3. Loading of Doxorubicin onto Magnetic Nanoparticles [48] 
The Dox-MNP were freeze dried in water as described above. A mixture of 2 mL 
of the 12.5% v/v methanol/chloroform was added to 2 mg of the Dox conjugated MNP 
and shaken overnight. MNP were separated from the solution using neodymium magnets 
(Grade N52 CMS).  After separation of the MNP, 1.5 mL of the remaining clear solution 
was removed and dried out in a preweighed tube. To determine the Dox loading, 1.5 mL 
DMSO was added to remove the Dox and was read in triplicates on the Tecan fluorimeter 
(Männedorf, Switzerland) plate reader at excitation 485 nm, and emission at 591 nm for 
the h-Dox.  
5.2.4. Magnetic Behavior of MNP Loaded with h-Dox:Vibrating Sample Magnetometer  
Magnetization of MNP-OA samples with and without Dox loading was measured 
at 300 K where samples were placed in a uniform magnetic field and sinusoidal physical 
vibrations were applied. The voltage induced by the MNP was picked up by the coils. 
The magnetization was recorded for the field between -4000 Oe to 4000 Oe at 100 Oe 
intervals. Eun Ju Moon from the Materials Department performed this Vibrating Sample 
Magnetometer VSM test. 
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5.2.5. Fabrication of Drug or Nanoparticle Loaded Ultrasound Contrast Agents  
The following fabrication method was developed by Dalia El Sherif and modified 
by Kelleny Oum [51] [52]. Poly (lactic acid) UCA was made using the double emulsion 
technique (w/o/w). At room temperature, 500 mg of PLA and 50 mg of camphor were 
dissolved in 10 mL of methylene chloride, covered with aluminium foil and stirred in a 
50 mL beaker. In another small beaker, 400 mg of ammonium carbonate was dissolved in 
10 mL of DI water. The loading of the drug or the nanoparticles depend on their 
hydrophilic behavior; when it is hydrophobic, it is added to the methylene chloride 
mixture, otherwise, it is added to the ammonium carbonate mixture. After dissolution, 1 
mL of the ammonium carbonate solution was added to the polymer mixture and it was 
sonicated in an ice bath using Misonix probe sonicator at 110 W for 30 seconds which is 
made up of 10 pulses of 3 seconds on, separated by 1 second off each. The sonicated 
solution was added to 50 mL of cold (4
o 
C) 5% poly vinyl alcohol (PVA) in a 500 mL 
beaker. Thereafter, it was homogenized with a Brinkmann PT 3100 homogenizer with a 
Polytron PT-DA 3020/2 generator for 5 min at (2000 g-force, 9.6k rpm). Then 100 mL of 
2% v/v isopropyl alcohol (IPA) was added to the homogenized mixture and the top was 
partially covered with parafilm. The mixture was stirred on a magnetic stir plate for 1.5 
hour at 375 rpm to evaporate the methylene chloride. The mixture was poured into 4 
tubes of 50 mL maximum volume tubes and centrifuged using Beckman Coulter, 
Allegra
TM
 21 centrifuge at 5000 rpm (2.6k g-force) for 5 min. The supernatant was 
discarded while the microbubbles were combined into one tube before re-centrifuging 
them for 5 min at 5000 rpm. The supernatant was discarded and the microbubbles were 
gently washed with hexane three times. The remaining hexane from the microbubbles 
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was allowed to evaporate in the chemical fume hood for 30 min. DI water was added and 
the mixture was re-centrifuged for 5 min at 5000 rpm (2.6k g-force). The supernatant was 
discarded. The tube was covered with a Kim wipe and an elastic band before flash 
freezing the microbubbles in liquid nitrogen. The frozen microbubbles were put into the 
Vitris Benchtop freeze dryer (Gardiner, NY) for 72 hours in order for water, ammonium 
carbonate and camphor to sublime.  
5.2.6. Characterization of the Ultrasound Contrast Agents 
5.2.6.1. Zeta potential and Size of the Ultrasound Contrast Agent 
Using the Malven’s Zetasizer nano ZS (Worcestershire, UK) and DTS Nano 
software, the following tests were performed. 1 mg of the fabricated sample was 
suspended in 1 mL PBS and tested in DTS0012 for size determination and Polydispersity 
Index (PDI). Similarly, 1 mg of fabricated sample was suspended in DI water in a 
Malvern zeta capillary cuvette DTS1060 for the zeta potential testing in the Zetasizer. 
The samples were measured in triplicate and particle sizes were reported as peak % 
number. 
5.2.6.2. Cumulative Dose Response: contrast enhancement as a function of ultrasound 
contrast agent dosage 
The test system consisted of one directional pulsed A-mode ultrasound system 
with a single element, broadband, 12.7 mm element diameter, 50.8 mm spherically 
focused transducer with center frequency of 5 MHz with a -6 dB bandwidth of 92% as 
shown in Figure 5-1.  A sample vessel containing 50 mL of the phosphate buffered saline 
(PBS at pH 7.4) was settled inside the deionized water bath at 37° C. The oscilloscope 
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was turned on and the pulser/receiver (model 5072 PR, Panametrics, Inc., Waltham, MA) 
that sends pulses to the transducer at a repetition frequency (PRF) of 100 Hz was focused 
though an acoustic window on the sample vessel using an x-y positioning system 
(Edmund Scientific, Barrington, NJ). The received signals was amplified by 40 dB and 
delivered to the digital oscilloscope (Lecroy 9350A, Lecroy, Chestnut Ridge, NY). 800 
μL of the PBS was removed from the sample vessel and was added to the 3 mg of the 
microbubbles. It was vortexed for 30 seconds until all the microbubbles were suspended 
evenly. A 20 μL sample of the microbubble mixture was added to the sample vessel 
every minute which was repeated 10 times. The LabView Main Ultrasound Program was 
used to collect data times to create a cumulative dose response curve.  
 
 
 
Figure 5-1 Schematic of the in vitro acoustic testing set-up, image courtesy of Tarn Teraphongphom 
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5.2.6.3. Time Response: stability of the agent during continuous insonation 
A sample vessel containing 50 mL of PBS at pH 7.4 was placed inside the water 
bath. The oscilloscope and the pulser/receiver were turned on and the transducer was 
focused on the sample vessel using the x-y positioning system. A dose that was within the 
linear part of the dose response curve was added to the PBS and was insonated 
continuously with a PRF of 100 Hz and a peak negative pressure amplitude of 0.45 MPa 
(energy 1) and 0.94 MPa (energy 4) [53]. The LabView Main Ultrasound Program was 
used to collect the data.  
5.2.6.4. Scanning Electron Microscopy 
Environmental scanning electron microscope (SEM) (FEI XL30, Hillsboro, OR) 
was used to take images of UCA. Around 1 mg of the lyophilized UCA was gently fixed 
on a carbon tape and using a Denton Desk-II sputtering system (Denton Corp, NJ), the 
sample was sputter-coated with platinum for 3 seconds. Images of the samples at various 
magnifications was taken at accelerating voltage of 5 kV and a spot size was 3. All 
sputter coating and SEM imaging were performed in the Drexel University Central 
Research Facility by Wheatley Lab’s designated SEM imaging personnel, Lauren 
Jablonowski. These images were used to determine the morphology of the fabricated 
samples. 
5.2.7. Doxorubicin Loading 
Approximately 2 mg of fabricated Dox containing PLA microbubbles was added 
to 2 mL DMSO and vortexed for 30 seconds until the polymer had dissolved. A Tecan 
fluorimeter (Männedorf, Switzerland) was used to read the fluorescence of the mixture at 
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an excitation wavelength of 495 nm and an emission wavelength of 585 nm for the 
hydrophilic Dox and excitation wavelength of 485 nm and an emission wavelength of 
591 nm for the h-Dox. These excitation and emission wavelengths for the h-Dox were 
determined using the fluorescence scans. All samples were read in triplicate. Doxorubicin 
concentrations were calculated based on standard curves of known amounts of Dox in 
DMSO. The loading and encapsulation of the Dox on the UCA were determined using 
Eq. 4 and Eq. 5.  
100% 
WeightUCATotal
WeightDoxFinal
Loading         Eq. 4 
100% 
WeightDoxInitial
WeightDoxFinal
EfficiencyionEncapsulat      Eq. 5 
5.3. Statistical Methods 
Statistically significant differences between multiple groups were determined 
using one-way analysis of variance (ANOVA) and multi-compare function using 
MATLAB. Statistical significance was determined using 95% confidence interval 
(p=0.05). Error bars were displayed as standard error about the mean (SEAM). 
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6. RESULTS AND DISCUSSION 
The main goal of this research was to create PLA UCA that would have increased 
Dox payload in order to improve patient treatment. The systemic side effects of the Dox 
could be decreased while increasing safety since there would be a reduction in the dose of 
drug administered. This goal was hypothesized to be possible through increasing the 
surface area of the PLA UCA on which the Dox can be entrapped as well as increasing 
Dox’s affinity to be encapsulated.  
Magnetic nanoparticles capped with oleic acid were synthesized in the first phase 
of the experiment. The effects on the structure and acoustic properties of the UCA as a 
result of increasing the MNP-OP loading in UCA were tested. These samples were made 
immediately after the fabrication of the MNP-OA. Magnetic nanoparticles capped with 
oleic acid were observed to be unstable and sink in the methylene chloride solution after 
one week of synthesis which resulted from losing their capping agent. Ultrasound 
contrast agents made from these were found to be non echogenic. Therefore, another 
method of synthesis was investigated to create magnetic nanoparticles capped with oleic 
acid. They were further coated with Pluronic acid. During the second phase of the 
experiment, the Dox payload and entrapment efficiency of MNP-OA-PA were tested. 
Microbubbles loaded with various amounts of MNP-OA-PA were also fabricated and 
tested for their acoustic properties. Samples of h-Dox were made and encapsulated in 
UCA to determine whether the resulting payload of Dox would be increased by using the 
hydrophobic form. The tests to compare the structure and acoustic properties of these h-
Dox loaded UCA to that of the hydrophilic Dox were also performed.  
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Aim 1 – Loading of Magnetic Nanoparticles on Ultrasound Contrast Agents 
The co-precipitation method of synthesizing MNP-OA yielded 503±34 mg with a 
yield percent of 63.32%.   These were encapsulated in PLA UCA by adding them in the 
methylene chloride along with the PLA during the fabrication process.  33 wt% MNP-OA 
encapsulated UCA had 250 mg loaded onto them while the 50 wt% MNP-OA 
encapsulated UCA had 500 mg loading. Apart from the aforementioned loadings, the 
fabrication method was the same as the unloaded UCA which were used as controls in 
the following tests. 
6.1.1. Acoustic Properties of MNP-OA Loaded UCA 
The effect of MNP-OA loading in the PLA-UCA on the in vitro acoustic 
properties were tested using the set up shown in Figure 5-1. Figure 6-1 shows the in vitro 
enhancement of the various loadings of the MNP-OA compared to the unloaded UCA, 
the control.    
The maximum enhancement of the unloaded sample was at 18.81±0.52 dB at the 
6.12 μg/mL dose. Thereafter, the acoustic enhancement decreased to 16.89 dB at the 
15.30 μg/mL dose due to shadowing. Shadowing is caused by the inability of ultrasound 
waves to pass through a dense concentration of UCA and the inability for the backscatter 
from the UCA to reach the transducer due to it being reflected continuously between the 
focal point and the transducer [54-55]. The hindrance was increased with dose.   
Similar shadowing pattern are seen in the dose response curve of the 33 wt% 
MNP-OA loaded UCA which reached the highest acoustic enhancement of 14.77±0.61 
dB at 6.12 μg/mL dose level. This acoustic enhancement is significantly lower than the 
control UCA (p<0.0001). The overall dose dependent acoustic enhancement of the 50 
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wt% MNP-OA loaded UCA was also significantly lower than the unloaded which has the 
maximum of 12.73±0.80 dB, read at a high dose of 15.3 µg/mL (p<0.0001). This was 
also lower than the 33 wt% MNP-OA UCA (p<0.05). No shadowing effect was seen in 
50 wt% MNP-OA loaded UCA.  There was no statistically significant difference in 
acoustic enhancement between the two MNP-OA loaded UCA at 15.3μg/mL.  
These results suggest that loading the MNP-OA shows decreased acoustic 
enhancement by the UCA. The absence of the shadowing effect by the 50 wt% MNP-OA 
when compared to the 33 wt% MNP-OA could be due to fewer acoustically active 
microbubbles per dose. Addition of the MNP-OA onto the UCA can successfully result in 
acoustic enhancements over the acceptable enhancement of 14 dB. 
 
  
 
 
 
 
 
The stability of the MNP-OA loaded UCA when subjected to in vitro ultrasound 
was also tested as shown in Figure 6-2. All three samples had some degree of loss of 
enhancement within 15 minutes of subjecting the UCA to ultrasound but their half lives 
Figure 6-1 The effect of varying MNP capped with oleic acid loading on the acoustic enhancement of UCA 
(n=3, error bars=SEAM) 
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were all more than 15 minutes. 50 wt% MNP-OA stability decreased over time,  
however, 33 wt% MNP-OA loaded UCA showed that they can be significantly more 
stable when compared to the blank UCA (p=0.0029). As seen with the 33 wt% MNP-OA, 
adding some MNP-OA can strengthen the shell of the UCA, enabling them to withstand 
the forces exerted by the ultrasound longer.   
 
 
From the two different loadings of MNP-OA, 33 wt% MNP-OA had better 
acoustic properties; both acoustic enhancement and stability were higher than that of 50 
wt% MNP-OA when subjected to ultrasound.  
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Figure 6-2 The effect of varying MNP capped with oleic acid loading on the stability of the UCA (n=3, 
error bars=SEAM) 
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6.1.2. Size and Surface Properties of the MNP-OA Loaded UCA 
No statistically significant differences were seen among the 3 samples in terms of 
size as shown in Figure 6-3 (p>0.05). Loading MNP-OA onto the UCA did not affect the 
size of the fabricated UCA since the size of the 33 wt% MNP-OA and 50 wt% MNP-OA 
were 1847±227 nm and 2213±390 nm. The unloaded sample was 2044±78 nm. 
Therefore, size was not a factor that can explain the differences seen in the acoustic 
enhancement and stability of the loaded UCA.  
 
 
 
 
 
 
 
 
The 33 wt% MNP-OA had a PDI of (0.270±0.020). Only the unloaded 
(0.212±0.027) and the 50 wt% MNP-OA (0.307±0.024) were statistically different from 
each other in terms of PDI (p=0.0336) (Figure 6-4). The 50 wt% MNP-OA was the most 
poly dispersed sample and this could mean that some of the mass in the final lyophilized 
Figure 6-3 The effect of varying the loading mass of MNP capped with oleic acid on the size of UCA (n=3 
except 50 wt% MNP-OA, n=2, error bars=SEAM) 
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product may not be hollow UCA that are echogenic but small solid particles. However, 
all samples had a polydispersity index less than 0.7; a value above which samples are 
considered to have a broad size distribution. 
 
 
 
  
 
 
 
SEM images shown in Figure 6-5 showed more evidence of the presence of small 
spherical particles fabricated in the MNP-OA loaded UCA. Since they are small, it could 
be possible that there is no gas core within them. Since these were present in each dose 
that was added to the sample vessel, the acoustic enhancements were lower overall for 
the loaded particles. There were more wrinkled and poorly formed particles present in the 
50 wt% MNP-OA loaded UCA compared to the 33 wt% MNP-OA, which may also 
explain the lower acoustic enhancements of the 50 wt% MNP-OA loaded UCA. It may 
seem that the particles in B and C of Figure 6-5 do not reflect the size measurements 
shown in Figure 6-3. However, the size results are not the average size of the sample but 
the size at which most of the particles were formed. 
Figure 6-4 The effect of varying the loading mass of MNP capped with oleic acid on the polydispersity of 
the UCA made (n=3, error bars=SEAM) 
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The charge on the three groups as measured by zeta potential was significantly 
different from each other (p<0.05) (Figure 6-6). The controls had a significantly more 
negative charge (-29.35±1.02 mV) when compared to the 50 wt% MNP-OA loaded UCA. 
The zeta potential values for 33 wt% and 50 wt% MNP-OA loading was -25.83±1.35 mV 
and -14.25±0.93 mV. Since 50 wt% MNP-OA was of more positive zeta potential, it 
could clamp together when injected into the patient. The oleic acid capping makes the 
MNP hydrophobic, thus causing an increase in the zeta potential of the MNP-OA loaded 
UCA. This could suggest the presence of MNP-OA on the surface of the PLA shell and 
that MNP-OA was not present only inside the shell or the core of the UCA.  This could 
further explain  the appearance of a rough surface on the spherical UCA seen in Figure 6-
Figure 6-5 SEM images comparing the morphology of the UCA loaded with MNP capped with oleic acid. 
Top row has magnification of 10 000x while the bottom row is at 3000x. All size bars are 1um. Image (A) 
unloaded control UCA (B) 33wt% MNP-OA (C) 50wt% MNP-OA (D) unloaded control UCA (E) 33 wt% 
MNP-OA (F) 50 wt% MNP-OA 
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5 (B) 33 wt% MNP-OA and (C) 50 wt% MNP-OA at   10 000x magnification when 
compared to (A) the unloaded control sample. 
 
  
 
 
 
 
 
 
6.1.3.  Storage behavior of MNP-OA 
The MNP-OA which had been synthesized were dispersed in methylene chloride 
and were stored in the 4˚ C refrigerator. It was observed that after one week, the magnetic 
nanoparticles would settle to the bottom of the vial. Any bubbles made from these were 
found to be non echogenic (n=3). The capping agents, oleic acids, may disperse over time 
in the methylene chloride, causing the magnetic nanoparticles to be attracted to each 
other and clump together. The previous design was modified to ensure that the magnetic 
nanoparticles did not lose their capping agents to the methylene chloride solution, since 
these are vital in entrapping the Dox to the MNP.  
Figure 6-6 The effect of varying the loading mass of the MNP capped with oleic acid on the zeta potential 
of the UCA (n=3, error bars=SEAM) 
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Aim 2 – Entrapment of Doxorubicin onto Magnetic Nanoparticles 
Magnetic nanoparticles which are capped with the oleic acid were further coated 
with Pluronic acid so that the oleic acid would not be dispersed into solution, but instead 
surround the magnetic nanocrystals. Figure 2-7 shows the proposed design of this 
nanoparticle design. The entrapment and unloading method used by Jain et al was closely 
followed [49]. Firstly, the hydrophilic Dox was converted to its base form using TEA by 
a procedure described by Kwon [50]. When TEA was added to the Dox in aqueous 
solution, it changed the color from red to purple. The h-Dox base was extracted from the 
salts using chloroform, which gradually developed a dark orange color. The chloroform 
containing the Dox base was collected and evaporated off using the rotary evaporator to 
form a dark red solution. The remaining chloroform was left to be evaporated off for 4 
days in the chemical hood to ensure that as much chloroform as possible was removed. 
The yield was used to calculate the ratio of h-Dox made when compared to the amount of 
Dox-HCl that was initially used. Assuming that h-Dox is made from the reaction between 
TEA and Dox-HCl, the concentration of the Dox-HCl that was left in the water after the 
extraction with chloroform was determined. Figure 10-1 found in the Appendix section 
shows the standard curve that was used to determine the mass of the Dox-HCl left behind 
in the water. 98.84 % yield was found (n=1). The amount of Dox loaded on to the MNP 
when 1 mg of h-Dox was loaded onto 10 mg of MNP-OA-PA was determined using the 
following standard curve found in Figure 10-1. It was found that 0.288 mg h-Dox was 
loaded on each 1 mg of MNP-OA-PA (n=1). A vibrating magnetometer was used to 
determine whether magnetization of the MNP-OA-PA was affected by the loading of the 
h-Dox and the results are shown in Figure 6-7. There was no change in the overall 
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magnetization which indicates that the Dox is not interacting directly to the magnetic 
crystal core. 
 
 
 
 
 
 
 
 
  
Figure 6-7 Comparison in magnetization with and without loading h-Dox on MNP capped with oleic acid 
and coated with pluronic acid. It was measured at 300 K at room temperature 
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6.2.1. Characterization of MNP-OA-PA loaded UCA 
While the h-Dox loading onto the magnetic nanoparticles was carried out in the 
previous section, the loading of the new MNP-OA-PA onto the UCA was being tested.  
Since the MNP-OA loaded UCA were found to be non echogenic when 1 week old 
MNP-OA particles were used, Pluronic acid coated MNP-OA were loaded onto the UCA 
to determine whether the acoustic properties were as similar to when they were not 
coated with pluronic acid.  
Contrast agents were prepared loaded with 26 mg, 56 mg and 250 mg of MNP-
OA-PA, which correspond to 5 wt%, 10 wt% and 33 wt% of the overall UCA. The 
acoustic enhancement of all the MNP-OA-PA loaded samples was found to be lower than 
6 dB, equivalent to baseline. In an attempt to identify the cause of this, UCA agents were 
loaded with 54 mg pluronic acid (10 wt% pluronic acid UCA). This loading mass was 
determined by the ratio of pluronic acid added to the MNP-OA during its fabrication. 
Using this assumption, 54 mg was the amount of pluronic acid expected to be present in 
the 250 mg MNP-OA-PA loaded UCA.  With the exception of the 26 mg MNP-OA-PA 
in MeCl, other samples were added to the UCA fabrication process along with the 
ammonium carbonate dissolved in water since the particles were believed to be 
hydrophilic. The particles loaded with MNP-OA-PA were relatively similar in size to the 
unloaded control in Figure 6-8. The Pluronic acid UCA and Dox-PVA-MNP UCA 
showed smaller UCA formation but they were more dispersed as seen in Figure 6-9.  
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Figure 6-8 The effect of varying the loading mass of MNP capped with various molecules on the size of 
UCA (n=1, error bars=SEAM) 
Figure 6-9 The effect of varying the loading mass of MNP capped with various molecules on the 
polydispersity index of UCA (n=1, error bars=SEAM) 
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Scanning electron microscope images supported this claim as seen in Figure 6-10. 
The UCA present were much smaller and there were many unformed UCA present in 
those with higher Pluronic acid present in the UCA. This could further support the 
hypothesis that the Pluronic acid may be interacting with the UCA structure. Additional 
samples to make the n=3 and testing decreasing loadings to the mass of Pluronic acid 
found in the 5 wt% MNP-OA-PA could make the data conclusive. Decreasing the loading 
of the MNP-OA-PA decreased the size dispersity in the final UCA made.  
 
 
 
 
Figure 6-10 SEM images comparing the morphology of the UCA loaded with MNP-OA-PA. Magnification 
is 3500x. All size bars are 2.5μm. Image (A) 250 mg MNP-OA-PA in Aq (B) 56 mg MNP-OA-PA in Aq 
(C) 26 mg MNP-OA-PA in Aq (D) blank control UCA (E) 54 mg pluronic acid in Aq  
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The zeta potentials of the 10 wt% and 33 wt% were not reported due to problems 
with the zetasizer, but all other samples’ data are shown in Figure 6-11. The decreased 
zeta potential in Pluronic acid loaded UCA when compared to the control and the 26 mg 
MNP-OA-PA loaded could be due to modifications in the overall charge caused by the 
presence of hydrophilic ends. Since they were more negative, they would not cause any 
clamping.  
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Due to the lack of acoustic enhancements seen with UCA loaded with MNP-OA-
PA samples, a new type of fabrication methods should be considered. The interference 
with the acoustic enhancement of the UCA when loaded with the MNP-OA-PA along 
with low entrapment of the Dox into the nanoparticles, make this strategy to increase the 
loading of the Dox onto the UCA using MNP a design that requires a much more 
extensive review than is within the scope of this thesis.  
Figure 6-11 The effect of varying the loading mass of MNP capped with various molecules on the zeta 
potential of UCA (n=1, error bars=SEAM) 
48 
 
Aim 3 – Increasing Doxorubicin Loading onto Ultrasound Contrast Agents 
It was hypothesized that encapsulating the hydrophobic form of the doxorubicin 
into the PLA UCA would increase the drug encapsulation. This is mainly due to the 
deprotonation of the glycosidic amino group of the Dox-HCl by the TEA, which make it 
hydrophobic. Since methylene chloride, also called dichloromethane, is a polar solvent, 
during the UCA fabrication process, the h-Dox would be more attracted to the methylene 
chloride rather than the PLA which is uncharged. On the other hand, when it is in its 
hydrophobic form, the methylene chloride would made it favorable for the less polar Dox 
to associate with the non polar PLA (Figure 6-12). Also, the papers in which Dox was 
loaded onto the MNP nanoparticles stabilized by hydrophobic capping agents first 
converted the Dox-HCl into the Dox base which also supported this direction of the 
project [48] [56]. In addition, in a previous study by Cochron et al, it was shown that 
loading a hydrophobic drug paclitaxel onto the shell of the PLA UCA can give a much 
higher maximum payload of 129.46±1.80 μg paclitaxel/ mg PLA [53]. Thus, altering the 
formulation of the desired drug into its hydrophobic form would increase loading into the 
PLA shell. 
 
Figure 6-12 Proposed design of the final design where h-Dox was encapsulated into the PLA shell 
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6.3.1. Doxorubicin Encapsulation 
In order to compare the amount of two forms of Dox loaded onto the UCA, 2 
different standard curves were made – one for the hydrophilic Dox (Figure 10-2) and one 
for the h-Dox (Figure 10-3). The fluorescence reading for each was done at their 
optimum wavelengths on their emission and excitation spectrum scans. The optimum 
gain attained for the standards were used to read the UCA samples dissolved in DMSO. 
The 3 wt% hydrophilic Dox loaded UCA which had been chosen in the previous study to 
have the optimal combination of high acoustic enhancement of 18 dB, tight size 
distribution of PDI 0.309 and 8 mg Dox/ g PLA was used as a control to which the h-Dox 
loaded UCA could be compared to results obtained in the previous study [8]. Compared 
to the 3 wt% hydrophilic Dox loaded UCA which had 9.46±0.28 mg Dox/g PLA, 3 wt% 
hydrophilic Dox loaded UCA had a significantly higher pay load of 17.75±0.42 mg 
Dox/g PLA (p<0.0001) (Figure 6-13). Doubling the initial loading from 30 mg Dox/g 
PLA to 60 mg Dox/g PLA significantly increase the payload to 27.18±0.39 mg Dox/g 
PLA (p<0.0001).  
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The encapsulation efficiency of the 3 wt% h-Dox loaded UCA had a significant 
increase from 26 % to 51 % when compared to 3 wt% hydrophilic Dox loaded UCA as 
shown in Figure 6-14. Increasing the loading to 60 mg Dox/g PLA decreased the 
encapsulation efficiency despite the higher drug payload. The increase in drug 
encapsulation would allow a higher dose of Dox to be delivered to the tumor with the 
same amount of agent administered to the patient. 
Figure 6-13 The effect of varying the loading of different forms of Dox on the drug payload (n=3, error 
bars=SEAM) (p<0.0001) 
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6.3.2. Acoustic Properties of Hydrophobic Dox Loaded UCA 
Unloaded microbubbles were used as controls to which the acoustic properties of 
the Dox loaded UCA could be compared to. The three Dox loaded samples did not have 
any shadowing affect as did the unloaded UCA (Figure 6-15). The highest acoustic 
enhancement was at 15.8±2.97 dB at 13.77 μg/mL for the 3 wt% hydrophilic Dox loaded 
UCA. The highest acoustic enhancement of 12.69±0.81 dB was seen at the largest dose 
recorded (15.3 μg/mL) for the 3 wt% h-Dox loaded UCA. Acoustic enhancement of the 
8.25±0.27 dB was seen at the largest dose recorded (15.3 μg/mL) for 5.66wt% h-Dox 
loaded UCA. Overall, the 3wt% loadings of the two Dox forms were significantly 
different from each other, h-Dox UCA being much lower than the hydrophilic ones. Both 
h-Dox loaded UCA had dose response curves that were still increasing their enhancement 
with dose at the largest dose recorded, making it possible that higher loading can increase 
Figure 6-14 The effect of varying the loading of different forms of Dox on the encapsulation efficiency 
(n=3, error bars=SEAM) 
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their acoustic enhancement. Compared to the 3 wt% hydrophilic Dox, the 3 wt% h-Dox 
had a significantly lower acoustic enhancement (p<0.05). 
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The stability of the Dox loaded bubbles was then tested as shown in Figure 6-16. 
It was observed that 3 wt% h-Dox was slightly more stable than the unloaded UCA at 
lower ultrasound energy of 1 and this difference significantly increased at energy 4. The 
half lives of 3 wt% h-Dox and 5.66 wt% h-Dox were much longer than 15 minutes for 
energy 1 ultrasound waves. Ultrasound at energy 4 was used to determine whether the 
UCA could be ruptured by ultrasound since they were seen to be very stable at energy 1. 
Energy 4 ultrasound were able to decrease the 3 wt% h-Dox to half its initial 
enhancement at 5 minutes, showing that h-Dox can be ruptured with ultrasound. 
Moreover, the hydrophilic Dox loaded UCA were less stable and had a half life of around 
9 minutes for energy 1. The charge on the hydrophilic Dox could have made the shells, 
Figure 6-15 The effect of varying the loading of different forms of Dox on the acoustic enhancement of 
UCA (n=3, error bars=SEAM. 
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which are made out of PLA, a hydrophobic compound, to be less stable while the 
presence of another hydrophobic compound in the shell increased its stability.  
 
6.3.3. Size and Surface Properties of the Hydrophobic Dox Loaded UCA 
The 3 wt% h-Dox loaded UCA had a significant increase in size compared to the 
unloaded control and to the 3 wt% hydrophilic Dox loaded UCA (p<0.05) (Figure 6-17). 
However, the size was still within the criteria since they were less than 5 μm. Figure 6-18 
shows that the UCA loaded with 3 wt% h-Dox were more uniform in size than other 
samples. This uniformity in size was also observed in the SEM images shown in Figure 
6-19.  
 
Figure 6-16 The effect of varying the loading of different forms of Dox on the stability of UCA (n=3, error 
bars=SEAM) 
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Figure 6-17 The effect of varying the loading of different forms of Dox on the size of UCA (n=3 for all 
except 5.66wt% h-Dox which has n=1, error bars=SEAM) 
Figure 6-18 The effect of varying the loading of different forms of Dox on the polydispersity index of the 
UCA (n=3 for all except 5.66wt% h-Dox which has n=1, error bars=SEAM) 
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The presence of many poorly formed microbubbles observed in the SEM image of 
the 5.66 wt% h-Dox loaded UCA could account for the low acoustic enhancement 
(Figure 6-15). These particles most probably do not have the gas core that could help 
reflect and scatter the incoming ultrasound waves.   
The zeta potentials in Figure 6-20 were unexpected since the hydrophobic and 
hydrophilic Dox encapsulation was thought to affect the charge of the bubbles formed 
differently. Both forms had a less negative surface charge than the unloaded UCA. The 
higher charge on the surface could be due to the Dox which was encapsulated in the shell 
Figure 6-19 SEM images comparing the morphology of the UCA loaded with doxorubicin. Magnification 
is 3500x. All size bars are 2.5μm. Image (A) blank control UCA (B) 3 wt% hydrophilic Dox (C) 5.66 wt% 
h-Dox (D) 3 wt% h-Dox 
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was in its hydrophobic form. Hydrophobic compounds would be uncharged so it could 
have decreased the charge of those h-Dox loaded UCA. The less negativity would make 
the bubbles more likely to flocculate. However, the zeta potential between the 3 wt% 
Dox-HCl and 3 wt% h-Dox were not significantly different (p>0.05). 
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Figure 6-20 The effect of varying the loading of different forms Dox on the zeta potential of UCA (n=3, 
error bars=SEAM) 
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7. CONCLUSIONS AND CONTRIBUTIONS TO SCIENCE 
In this thesis, increased loading of Dox on PLA UCA was achieved by changing 
the formulation of the Dox to make it more hydrophobic in order to increase its 
interaction with the hydrophobic PLA during the encapsulation process. This would 
increase its therapeutic effectiveness since more Dox could be delivered per μg of UCA 
injected into the patient and less microbubbles would need to be injected into the body, 
decreasing their chance of detection by the immune system.  This work is in agreement 
with previous work in this laboratory that showed that hydrophobic drugs such as 
paclitaxel are encapsulated at higher drug loadings than hydrophilic drugs such as Dox-
HCl.  
All design criteria and constraints about the acoustic properties, size and surface 
properties of UCA were met for this h-Dox loaded UCA design. The 3 wt % h-Dox 
loaded UCA were above the 12 dB cut off for the acoustic enhancement and have an in 
vitro half life of more than 15 minutes. Their size was less than the 5 μm cut-off, 
allowing them to travel through capillaries without causing embolisms. Their dispersity 
in size was also low enough to ensure that the size would not reach the 5 μm. In addition, 
the zeta potential was comparable to the 3 wt% Dox-HCl to ensure that clamping would 
not occur when administered. These characteristics also make them a functional 
ultrasound contrast agent and not just a control release agent.  
In addition, magnetic nanoparticles can be used to encapsulate Dox but they have 
a low loading, making them an inefficient way to increase the Dox loading in UCA. In 
addition, MNP-OA stored in methylene chloride for over a week should not be 
encapsulated in UCA since they lose their acoustic properties and are no longer dispersed 
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as expected for capped MNP. Further coating of MNP-OA with Pluronic acid proved to 
also make the UCA lose their echogenic properties since less spherical microbubbles 
were formed.  
From these experiments where different particles and molecules were loaded onto 
the wall of the PLA UCA, it was seen that acoustic properties of the UCA can be 
significantly affected. If MNP were to help increase the loading of Dox on UCA, the 
design should include the addition of the free h-Dox on the shell as well as the Dox 
loaded MNP, producing multimodal contrast agents. Other nanocrystals such as gold 
nanoparticles can also be used as possible agents of increasing Dox encapsulation on 
UCA.  
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8. FUTURE RECOMMENDATIONS 
Further tests can be carried out to determine the formation of nanoshards and the 
release of Dox in vitro cell cultures. Also, in vivo lab animal models can be used to test 
the actual therapeutic efficiency and possible immune responses to the h-Dox UCA. In 
order to further increase the Dox encapsulation onto the microbubbles, the maximum 
mass of hydrophilic Dox that could be loaded into the shell through dissolving the 
hydrophilic Dox in ammonium carbonate solution should also be explored. The 
maximum acoustic enhancement and physical properties such as size, zeta potential and 
PDI should also be determined. This can be used to optimize the amount of Dox-HCl 
loaded into the ammonium carbonate and the amount of h-Dox loaded inside the shell to 
get as much drug on the UCA without significantly decreasing their acoustic properties.  
The use of MNP in UCA can be used to create a multimodal contrast agent for 
diagnostic purposes as well as to track the uptake of the nanoshards. In order to make a 
more echogenic administration of the MNP-OA loaded UCA into the patient, the 
fabrication method can be optimized to remove unformed small clumps of PLA. A 
possible method would be cross-flow filtration, or differential centrifugation. Adding 
more wash steps where the sample can be centrifuged at different revolutions per minute 
and at different times should also be explored. The effect on the size and size dispersity 
should be investigated at each stage. 
The effect of other capping agents on MNP should also be tested to determine 
whether this would increase the loading of the Dox compared to this current model of 
oleic acid and pluronic acid capping. The compound that has hydrophilic ends and a 
hydrophobic middle can be used as a replacement for pluronic acid and oleic acid and 
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their acoustic properties can be tested. A combination of Dox loaded MNP and h-Dox 
encapsulation on the UCA can also be investigated to determine whether more Dox can 
be loaded.  
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y = 674.83x + 853.67 
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Hydrophilic Dox in DMSO Standard Curve 
Figure 10-1 Standard curve of h-Dox in water used to calculate the encapsulation efficiency on MNP 
capped with oleic acid and coated with pluronic acid (n=3, error bars=SEAM) 
Figure 10-2 Standard curve of hydrophilic Dox in DMSO used to calculate the encapsulation efficiency on 
UCA (n=3, error bars=SEAM, Ex= 495nm, Em= 585nm, Gain=118 dB) 
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Figure 10-3 Standard curve of h-Dox in DMSO used to calculate the encapsulation efficiency on UCA 
(n=3, error bars=SEAM, Ex= 485nm, Em= 591nm, Gain=120 dB) 
